Assessment of Thiopurine–based drugs according to Thiopurine S-methyltransferase genotype in patients with Acute Lymphoblastic Leukemia

Azimi F MSc1, Jafariyan M MSc3, Khatami S PhD2, Mortazavi Y PhD3, Azad M PhD4

1. M.S.c student of medical genetics, Zanjan University of Medical Science, Zanjan, Iran
2. PhD student of molecular medicine, Zanjan University of Medical Science, Zanjan, Iran
3. Associate professor of Hematology Zanjan University of Medical Sciences, Zanjan,Iran
4. Assistant professor in hematology, Ghazvin University of Medical Science, Ghazvin,Iran

Received: 29 August 2013
Accepted: 24 November 2013

Abstract
For the past half century, thiopurines have earned themselves a reputation as effective anti-cancer and immunosuppressive drugs.

Thiopurine S-methyltransferase (TPMT) is involved in the metabolism of all thiopurines and is one of the main enzymes that inactivates mercaptopurine. 6-MP is now used as a combination therapies for maintenance therapy of children with acute lymphocytic leukemia (ALL). In all patients receiving mercaptopurine, there is a risk of bone marrow suppression.

TPMT activity is inherited as a monogenic, co-dominant trait. More than 25 variants are known. Genetic testing is available for several TPMT variant alleles. Most commonly TPMT*2, *3A, and *3C are tested for, which account for >90% of inactivating alleles. Differences in DNA that alter the expression or function of proteins that are targeted by drugs can contribute significantly to variation in the responses of individuals. Genotyping may become part of routine investigations to help clinicians tailor drug treatment effectively. This success is mainly due to the development of combination therapies and stratification of patients according to risk of treatment failure and relapse, rather than the discovery of new drugs. The aim of this study was to investigate the effect of genotype or methyltransferase enzyme activity before starting therapy in children with ALL. This can prevent the side effect of thiopurine drugs. In fact, the common polymorphism of this enzyme in population could be a prognostic factor in relation to drug use and treatment of patients with ALL.

Keywords
Acute lymphoblastic leukemia; Azathioprine; 6-Mercaptopurine; 6-Thioguanine; Myelosuppression; Polymorphism

Corresponding Author:
Mortazavi Y, Assistant professor in hematology. Zanjan University of Medical Science, Zanjan, Iran. Email: ymortaza@zums.ac.ir

Introduction
Since the introduction of combination chemotherapy for the treatment of acute lymphoblastic leukemia (ALL) in children, the prognosis for this disease has improved steadily such that most trials now report a long-term survival rate of over 70%. However, current treatment protocols are complex and are associated with significant toxicity [1].

There are therefore two major priorities in the treatment of childhood ALL: further improvement in the survival rate and a reduction in treatment-associated toxic side effects. One method, which may be used to achieve these goals, is the more effective use of currently available chemotherapy. At present, most patients are given cytotoxic drugs at a dosage determined by their surface area, despite the fact that, for several of the agents used, there is good evidence that this results in marked differences in the amount of drug which reaches its target [2]. This is exemplified by the thiopurine, 6-mercaptopurine (6-MP), used in many regimes as part of the maintenance phase of therapy.

The level of expression of the enzyme thiopurine methyltransferase (TPMT) is an important determinant of the metabolism of thiopurines used in...
the treatment of acute lymphoblastic leukemia (ALL).

Thiopurine drugs (azathioprine, 6-mercaptopurine, thioguanine) are cytotoxic agents increasingly used to treat a variety of conditions including acute lymphoblastic leukemia, inflammatory bowel disease, Crohn's disease, and multiple sclerosis.

The importance of TPMT activity in the inactivation of 6-MP is demonstrated by the severe myelosuppression suffered by individuals with a congenital absence of the enzyme when given standard doses of 6-MP or the closely related drug azathioprine.

6-MP is the common component of regimen for intensive therapy as one of the best examples of the potential importance of pharmacogenetics on anti-cancer therapy as one of the best examples of the potential importance of pharmacogenetics on anti-cancer therapy. Specifically, it is now known that a reduction in TPMT activity, caused by genetic polymorphism, results in severe and sometimes fatal haematological toxicity in patients treated with standard doses of thiopurines such that the dose must be decreased for patients with heterozygous or homozygous polymorphisms in the TPMT gene. Conversely, patients with very high TPMT activity may be undertreated. Numerous genetic polymorphisms have been identified which are or may be associated with decreased levels of TPMT enzyme activity and/or enhanced toxicity of thiopurines [11].

This polymorphisms are distributed throughout the protein structure they all are able to exert an effect on the active site. The frequency of distribution of erythrocyte TPMT activity in 298 control subjects was found to be trimodal. Approximately 1 in 300 individuals (0.3%) had low undetectable levels of TPMT activity, with intermediate levels in approximately 10% of individuals [10].

Variant human alleles of TPMT proven to be associated with decreased catalytic activity can involve point mutations in the open-reading frame or at intron/exon splice sites. Patients that inherit one wild-type allele and one of the mutant alleles have intermediate TPMT activity while those that are

Metabolism of thiopurines

Mercaptopurine is inactivated by two different pathways, one being catalyzed by TPMT. Individuals who inherit two nonfunctional TPMT alleles (~1 in 178 to 1 in 3,736) experience life-threatening myelosuppression, due to high levels of TGNs, if they receive conventional doses of mercaptopurine. Individuals who are heterozygous for nonfunctional TPMT alleles (~3–14%) are at significantly higher risk for toxicity than individuals with two functional alleles. However, some of these individuals, ~40–70%, can tolerate the full dose of mercaptopurine. This may be because heterozygous-deficient individuals have lower concentrations of less active metabolites, such as MeMPN (methylmercaptopurine nucleotides), than homozygous-deficient individuals [3,4,5,6].

Another mercaptopurine inactivation pathway is oxidation, which is catalyzed by xanthine dehydrogenase, XDH (also known as xanthine oxidase). If this pathway is inhibited, catabolism of mercaptopurine is reduced leading to mercaptopurine toxicity. Therefore, a lower dose of mercaptopurine is required in patients taking the XDH inhibitor, allopurinol.

6-MP is a prodrug, which requires activation before it can exert its cytotoxic effects. As an analogue of hypoxanthine, it can act as a substrate for hypoxanthine guanine phosphoribosyltransferase (HGPRT) leading to the formation of 6-thioguanosinemonophosphate (TIMP). Sequential reactions involving thioinosinonemonophosphate dehydrogenase and guanine monophosphatesyntetase yields thioguanosine monophosphate (TGMP). Sequential reactions by phosphokinases yields thioguanosinediphosphate and triphosphate (TGDP and TGTP). TGMP, TGDP, and TGTP are collectively termed thioguanine nucleotides (TGNs, see Figure 1). Incorporation of 6-TGTP into DNA is believed to trigger cell death, probably by a process that involves the mismatch repair pathway [7,8].

Thiopurinemethyltransferase (TPMT)

Thiopurine methyltransferase (TPMT) is a cytosolic methylating enzyme whose physiological role, despite extensive investigations remains unclear. However, this enzyme is known to catalyze S-methylation of aromatic and heterocyclic compounds, preferentially thio compounds such as 6-MP and 6-TG.

It has a molecular mass of 26 kDa and is expressed in the liver, kidneys, intestine, erythrocytes, leukocytes and a number of other tissues [9]. The discovery that levels of TPMT activity in human tissues are influenced by a common genetic polymorphism represents themost important example of the influence of pharmacogenetics on anti-cancer therapy as one of the best examples of the potential importance of pharmacogenetics for clinical medicine ingeneral [10]. Specifically, it is now known that a reduction in TPMT activity, caused by genetic polymorphism, results in severe and sometimes fatal haematological toxicity in patients treated with standard doses of thiopurines such that the dose must be decreased for patients with heterozygous or homozygous polymorphisms in the TPMT gene. Conversely, patients with very high TPMT activity may be undertreated. Numerous genetic polymorphisms have been identified which are or may be associated with decreased levels of TPMT enzyme activity and/or enhanced toxicity of thiopurines [11].

These polymorphisms are distributed throughout the protein structure they all are able to exert an effect on the active site. The frequency of distribution of erythrocyte TPMT activity in 298 control subjects was found to be trimodal. Approximately 1 in 300 individuals (0.3%) had low undetectable levels of TPMT activity, with intermediate levels in approximately 10% of individuals [10].

Variant human alleles of TPMT proven to be associated with decreased catalytic activity can involve point mutations in the open-reading frame or at intron/exon splice sites. Patients that inherit one wild-type allele and one of the mutant alleles have intermediate TPMT activity while those that are
homzygous for mutant alleles are TPMT deficient. Other alterations detected in the TPMT gene include deletion of exons six and nine and polymorphisms in the variable number of tandem repeats [11,12,13].

Four alleles (TPMT*2, *3A, *3B, and *3C) account for ~95% of inherited TPMT deficiency and have been biochemically characterized [6,14,15,16]. The *3A allele results in an~400-fold decrease in protein levels and no detectable enzyme activity. The TPMT*3B allele results in a four-fold decrease in protein levels. The TPMT*2 allele contains an alanine to proline substitution at residue 80 that results in ~100-fold decrease in TPMT activity and very low levels of immunological protein and the TPMT*3C allele results in a 1.4-fold reduction in protein levels [17,18].

Several of these alleles cause rapid protein degradation and/or aggregation, making it extremely difficult to study the structural impact of the TPMT polymorphisms experimentally [19]. The TPMT gene encodes one of the main enzymes involved in the metabolism of thiopurines, such as mercaptopurine. TPMT activity is inherited as a monogenic, co-dominant trait. TPMT is highly polymorphic—more than 25 variants are known [20].

• TPMT*2 (238G>C)
• TPMT*3A (contains two SNPs, *3B and *3C)
• TPMT*3B (460G>A)
• TPMT*3C (719A>G)

The wild-type allele, TPMT*1, encodes the fully active enzyme; while TPMT*2, TPMT*3A and TPMT*3C are the most prevalent in Caucasians, accounting together 80 to 95% of the polymorphic alleles that lead to a significant reduction in enzyme activity due to enhanced rates of proteolysis of the mutant proteins [21].

The frequency of TPMT alleles varies among different populations. In the United States, the most common low-activity allele in the Caucasian population is TPMT*3A (~5%). This allele is also found in individuals who originate from India and Pakistan, but less frequently [22,23,24]. In East Asian, African-American, and some African populations, the most common variant is TPMT*3C (~2%), although TPMT*8 may be more common in African populations than previously thought (~2%). In general, TPMT*2 occurs much less commonly, and TPMT*3B occurs rarely [23,25].

Population studies in Caucasian, East and West African, African-American, Chinese, Japanese and Southwest Asian populations have demonstrated the utility of this approach [21,26,27,28]. However, the frequency and pattern of mutant TPMT alleles is different among various ethnic populations. For example, Southwest Asians (Indian, Pakistani) have a lower frequency of mutant TPMT alleles and all mutant alleles identified to date are TPMT*3A [21]. This is in contrast with the East and West African population in which the frequency of mutant alleles is similar to Caucasians, but all mutant alleles in the African populations are TPMT*3C [27,28]. Among African-Americans, TPMT*3C is the most prevalent, but TPMT*2 and TPMT*3A are also found, reflecting the integration of Caucasians and African-Americans genes in the US populations [26]. Mehdi Azad and al have shown in Iranian Population a prevalence of TPMT*2 was 7.08%. TPMT*3C and *3A were found in 2.47% and 2.18% of the samples, respectively. TPMT*3B variant was not detected in Iranian subjects. These results can help to organize national pretreatment strategies in patients with acute lymphoblastic leukemia (ALL) or other diseases requiring thiopurine medication in their standard therapy [29]. In other study, Mehdi Azad and et al have investigated the frequency of the most prevalent Thiopurine S-Methyl Trasferase alleles in referrals to Shariati Hospital in Tehran, and showed Mutant TPMT alleles were found in 11.8% of subjects (15 out of 127). Nine had TPMT*2, 4 TPMT *3C and 2 TPMT*3A. The data showed the necessity of TPMT polymorphisms assessment before administration of thiopurine drugs [30].

Pharmacokinetic and pharmacodynamic studies of 6-MP and 6-TG in TPMT knockout mice with high, medium and no TPMT activity indicated that 6-MP was significantly more affected by TPMT polymorphisms than 6-TG [31]. Those studies corroborated earlier research by Dervieux et al [32] who found that elevation of TPMT activity in human CCRF-CEM cell lines by retroviral genetransfer rendered the cells less sensitive to 6-TG, but more sensitive to 6-MP. This effect was also seen in another study by Couthard et al. [9] in which human embryonic kidney cells were transfected with TPMT cDNA under the control of an induciblesystem in which they showed a 4.4-fold increase in sensitivity to 6-MP and a 1.6-fold decrease in sensitivity to 6-TG.

TPMT activity is inversely related to TGN concentrations in theerythrocytes of children treated for leukemia [33]. High erythrocyte concentrations of TGNs are correlated with the degree ofleucopenia and a good prognosis [34] whereas low concentrations are associated with an increased risk for relapse [35]. Several recent studies have identified an interaction between 6-MP pharmacology and the incidence of secondary malignancies, including brain tumors after radiotherapy. At first thererults appear to be conflicting; however, these anomalies are most likely
to be protocol dependent. Essentially, for patients treated with the St. Jude Children’s Hospital protocols, low TPMT activity is associated with higher risk of secondary cancers, in contrast to patients treated with the BFM protocols where no such association was found [36].

**Genetic Testing**

Genetic testing is available for several TPMT variant alleles. Most commonly TPMT*2, *3A, and *3C are tested for, which account for >90% of inactivating alleles. Rare or previously undiscovered variants will not be detected by variant-specific genotyping methods [37].

Phenotype testing is also available. For example, the TPMT activity in red blood cells can be measured directly. However, the results will not be accurate in patients who have received recent blood transfusions [38]. Method for the measurement of mercaptopurine metabolites (TGN and MeMPN) are also available.

**Therapeutic Recommendations**

**FDA statement**

If a patient has clinical or laboratory evidence of severe toxicity, particularly myelosuppression, TPMT testing should be considered. Substantial dose reductions of mercaptopurine are generally required for homozygous-TPMT deficiency patients (two non-functional alleles) to avoid the development of life threatening bone marrow suppression. Although heterozygous patients with intermediate TPMT activity may have increased mercaptopurine toxicity, this is variable, and the majority of patients tolerate normal doses of mercaptopurine [38].

**CPIC statement**

Testing for TPMT status is recommended prior to starting mercaptopurine therapy, so that the starting dosages can be adjusted accordingly (see Table 1 for dosing recommendations). In homozygous variant individuals, consider an alternative agent for nonmalignant conditions and drastically reduce doses in malignant conditions. In heterozygous individuals, depending on the disease being treated, starting doses should be reduced. In both patient groups, a longer period of time should be left after each dose adjustment to allow for a steady state to be reached [6].

Most population studies of TPMT activity have used RBC as a convenient source of samples. Levels in RBC have been shown to reflect levels in other tissues, including lymphoblasts [39]. One major problem with the use of RBC is the fact that samples must be obtained before transfusion.

Previous reports in which levels of TPMT activity in RBC increased during maintenance therapy also suggests that epigenetic factors may affect the rate of transcription [40].

**Results**

During the time we have witnessed dramatic improvement in survival rates of leukemia patients. This success is mainly due to the development of combination therapies and stratification of patients according to risk of treatment failure and relapse, rather than the discovery of new drugs. Studies of pharmacogenetics designed to improve drug safety and efficacy have been already proven to be advantageous in the case of the influence of genetic polymorphisms in the TPMT gene on response to thiopurines.

Gene array technology should aid researchers in finding new targets for thiopurines and may help predict the response to these agents through comparison of the expression profiles of responsive and non-responsive patients. Application of HapMap tools or specially designed biochips to genotype TPMT already show great promise and could be modified to determine other important factors affecting thiopurine efficacy [41].

Although studies of the role of TPMT in determining the response of patients to continuing therapy have concentrated on the effects of this enzyme on drug conversion within leukemic cells, it is possible that variations in expression in the liver and intestine will also influence response through an effect on systemic pharmacokinetics. Family studies have shown that TPMT deficiency is inherited as an autosomal recessive trait [42].

There is also emerging evidence that these drugs are responsible for changes in methylation levels within the cells. The thiopurine drugs 6-MP, and MeMRP caused a reduction in DNA methylation in the T-cell acute lymphoblastic leukemia cell line MOLT-4 [43]. Hogarth et al. [42] have shown that there is a decrease in demethyltransferase (DNMT) activity and protein after thiopurine treatment which was influenced by TPMT for 6-TG, but was not influenced 6-MP in human embryonic kidney cells. As demethylating agents are known to be active in leukemia, it is possible that inhibition of DNA methylation by the thiopurine drugs may also contribute to their cytotoxic affects.

Ultimately, stratification of patients according to their general pharmacogenetic characteristics through application of expression profiling techniques could further improve treatments outcomes by providing individually tailored combination therapy.
Table I: TPMT phenotypes and the therapeutic recommendations for mercaptopurine therapy [6]

| Phenotype                        | Phenotype details                  | Genotype            | Examples of diplotypes | Therapeutic recommendations for mercaptopurine                                                                 |
|---------------------------------|------------------------------------|---------------------|------------------------|-------------------------------------------------------------------------------------------------------------|
| Homozygous wildtype (“normal”)  | High enzyme activity. Found in ~86–97% of patients. | Two or more functional alleles | *1/*1                  | Start with normal starting dose. Adjust doses of mercaptopurine along with concomitant medications. Allow 2 weeks to reach steady state after each dose adjustment. |
| Heterozygous                    | Intermediate enzyme activity. Found in ~3—14% of patients. | One functional allele plus one nonfunctional allele | *1/*2, *1/*3A, *1/*3B, *1/*3C, *1/*4 | Start with reduced doses (30–70% of the full dose). Adjust doses of mercaptopurine depending on degree of myelosuppression and disease-specific guidelines. Allow 2–4 weeks to reach steady state after each dose adjustment. |
| Homozygous and disease-specific guidelines. Allow 4–6 weeks to reach steady state after each dose adjustment | Low or deficient enzyme activity. Found in ~1 in 178 to 1~3736 patients. | Two nonfunctional alleles | *3A/*3A, *2/*3A, *3C/*3A, *3C/*4, *3C/*2, *3A/*4 | Consider alternative agents for nonmalignant conditions. For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily). Adjust doses of mercaptopurine based on degree of myelosuppression. |

Figure 1. The metabolism of 6-mercaptopurine.

Iranian Journal of Pediatric Hematology Oncology Vol4, No1
References

1. Waber DP, Tarbell NJ, Fairclough D, Atmore K, Castro R, Isquith P, et al. Cognitive sequelae of treatment in childhood acute lymphoblastic leukemia. J Clin Oncol. 1995;13(10):2490-6.

2. Evans WE, Relling MV. Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. Clin Pharmacokinet. 1989;16(6):327-36.

3. Higgs JE, Payne K, Roberts C, Newman WG. Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? Pharmacogenomics. 2010;11(2):177-88.

4. Black AJ, McLeod HL, Capell HA, Powrie RH, Matowe LK, Pritchard SC, et al. Thiopurine methyltransferase genotype predicts therapy limiting severe toxicity from azathioprine. Ann. Intern. Med. 1998;129:716-18.

5. Lennard L, Lilleyman J.S., Van Loon J, Weinshilboum, R.M. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet., 1990;336:225-29.

6. Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther. 2011;89(3):387-91.

7. Waters TR, Swann PF. Cytotoxic mechanism of 6-thioguanine: hMutSa, the human mismatch binding heterodimer, binds to DNA containing S-methylthioguanine. Biochemistry. 1997;36(9):2501-6.

8. Swann PF, Waters TR, Moulton DC, Xu YZ, Zheng QG, Edwards M, et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science. 1996;273(5278):1109-11.

9. Coulthard S, Hogarth L. The thiopurines: an update. Invest New Drugs. 2005;23(6):523-32.

10. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurinemethyltransferase activity. Am J Hum Genet. 1980;32(5):651-62.

11. Salavaggione OE, Wang L, Wiepert M, Yee VC, Weinshilboum RM. Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics. Pharmacogenet Genomics. 2005;15:801-15.

12. Alves S, Amorim A, Ferreira F, Prata MJ. Influence of the variable number of tandem repeats located in the promoter region of the thiopurine methyltransferase gene on enzymatic activity. Clin Pharmacol Ther. 2001;70(2):165-74.

13. Yan L, Zhang S, Eiff B, Szumlanski CL, Powers M, O'Brien JF, et al. Thiopurine methyltransferase polymorphic tandem repeat: genotype-phenotype correlation analysis. Clin Pharmacol Ther. 2000;68(2):210-9.

14. Alvarez LL, Venegas MS, Larrodo LM, Becerra NB, Castro AL, Quera RP. Thiopurine S-methyltransferase gene polymorphism in Chilean blood donors. Rev Med Chil. 2009;137(2):185-92.

15. Salavaggione OE, Wang L, Wiepert M, Yee VC, Weinshilboum RM. Thiopurine S methyltransferase pharmacogenetics: variant allele functional and comparative genomics. Pharmacogenet Genomics. 2005;15:801-15.

16. Szumlanski C, Otterness D, Her C, Lee D, Brandiff B, Kessell D, et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol. 1996;15(1):17-30.

17. Tai HL, Krynetski EY, Schuetz EG, Yanishevski Y, Evans WE. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc. Natl Acad Sci U S A. 1997;94(12):6444-9.

18. Wang L, Nguyen TV, McLaughlin RW, Sikkink LA, Ramirez-Alvarado M, Weinshilboum RM. Human thiopurine S-methyltransferase pharmacogenetics: variant allozyme misfolding and aggresome formation. Proc Natl Acad Sci U S A. 2005;102(26):9394-9.

19. Karen Rutherford, Valerie Daggett. Four Human Thiopurine S-Methyltransferase Alleles Severely Affect Protein Structure and Dynamics. J. Mol. Biol. 2008;379(4):803-14.

20. Wang L, Pellemounter L, Weinshilboum R, Johnson JA, Hebert JM, Altman RB, et al. Very important pharmacogene summary: thiopurine S-methyltransferase. Pharmacogenet Genomics. 2010;20(6):401-5.

21. Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med. 1997;126(8):608-14.

22. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukemia. Lancet. 1990;336:225-29.

23. McLeod HL, Miller DR, Evans WE. Azathioprine induced myelosuppression in thiopurine methyltransferase deficient heart-transplant recipient. Lancet. 1993;341(8853):1151.

24. Schutz E, Gummert J, Mohr F, Oellerich M. Azathioprine induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet. 1993;341(8842):436.
25. Krynetski EY, Evans WE. Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm. Pharm Res. 1999;16(3):342-9
26. Hon YY, Fessing MY, Pui CH, Relling MV, Krynetski EY, Evans WE. Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum Mol Genet. 1999;8(1):371-6.
27. Ameyaw MM, Collie-Duguid ESR, Powrie RH, Ofori-Adjei D, McLeod HL. Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum Mol Genet. 1999;8(2):367-70.
28. McLeod HL, Pritchard SC, Githang’a J, Indalo A, Ameyaw MM, Powrie RH, Booth L, Collie-Duguid ESR. Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specificity in Caucasian and Kenyan subjects. Pharmacogenetics, 1999; 9: 773–6.
29. Azad, M, Kaviani, S, Soleimani, M, Noruzinia, M, Hajfathali, A. Common Polymorphism's Analysis of Thiopurine S-Methyltransferase (TPMT) in Iranian Population. Yakhteh Medical Journal. 2009; 11(3):311-316.
30. Azadi, M, Kaviani, S, & Soleimani, M. Frequency of the most prevalent Thiopurine S-Methyl Transferase alleles in referrals to Shariati Hospital in Tehran. ISMJ. 2009; 12(1), 1-7.
31. Hartford C, Vasquez E, Schwab M, Edick MJ, Rehg JE, Grosveld G, et al. Differential effects of targeted disruption of thiopurine methyltransferase on mercaptopurine and thioguanine pharmacodynamics. Cancer Res. 2007;67(10):4965-72.
32. Dervieux T, Blanco JG, Krynetski EY, Vamin EF, Roussel MF, Relling MV. Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. Cancer Res. 2001 Aug 1;61(15):5810-6.
33. Lennard L, Van Loon JA, Lilleyman JS, Weinshilboum RM. Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther. 1987;41(1):18-25.
34. Lilleyman JS, Lennard L. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukemia. Lancet. 1994;343(8897):1188-90.
35. Boström B, Erdmann G. Cellular pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia. Am J Pediatr Hematol Oncol. 1993;15(1):80-6.
36. Schmiegelow K, Forestier E, Kristinsson J, Söderhäll S, Vettenraanta K, Weinshilboum R, et all. Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Leukemia. 2009;23(3):557-64.
37. Tai HL, Krynetski EY, Yates CR, Loennechen T, Fessing MY, Krynetskaia NF, et all. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet. 1996;58(4):694-702.
38. PURINETHOL® (mercaptopurine) 50-mg Scored Tablets [package insert]. Sellersville, PA: Gate Pharmaceuticals; (2011). [cited 2012 July 23]. Available from: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9af557d-37bf-4078-888e37c086dfce69.
39. McLeod HL, Relling MV, Liu Q, Pui CH, Evans WE. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood. 1995;85(7):1897-902.
40. McLeod HL, Relling MV, Liu Q, Pui C-H, Evans WE. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood. 1995;85(7):1897-902.
41. Kerstens PJ, Stolk JN, De Abreu RA, Lambooy LH, van de Putte LB, Boerbooms AA. Azathioprine-related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):142-5.
42. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980;32(5):651-62.
43. Stet EH, De Abreu RA, Bökkerink JP, Blom HJ, Lambooy LH, Vogels-Mentink TM, et all. Decrease in S-adenosylmethionine synthesis by 6-mercaptopurine and methylmercaptopurine ribonucleoside in Molt F4 human malignant lymphoblasts. Biochem J.1994;304(1):163–8.
44. Hogarth LA, Redfern CP, Teodoridis JM, Hall AG, Anderson H, Case MC, et all. The effect of thiopurine drugs on DNA methylation in relation to TPMT expression. Biochem Pharmacol. 2008;76(8):1024-35.
Case Report

Mosaic and partial monosomy of chromosome 21 in a case with low platelets count

Hashemi A MD, Sheikhha MH MD PhD, Manouchehri MA MD, Kalantar SM PhD

1. Department of Pediatric Hematology oncology and Genetic Research Center, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran
2. Associate Professor in Genetics, PhD, Genetic Dept. Research & Clinical Centre for Infertility, Yazd, Iran
3. Pediatric, Main University Hospital, Yazd Medical Sciences University, Yazd-Iran
4. Associate Professor in Genetics, PhD, Genetic Dept. Research & Clinical Centre for Infertility, Yazd, Iran

Received: 3 July 2013
Accepted: 28 December 2013

Abstract

Background
Monosomy 21 as a sole cytogenetic abnormality has been reported in a wide variety of hematological disorders, a clear clinical pattern has yet to emerge. Until now, 47 cases of monosomy 21 mosaicism have been described in the literature (1). In this report, a 6 years old girl was presented who was referred to the Pediatric Dep, Shahid Sadoughi Hospital, Yazd, Iran, with partial monosomy of chromosome 21.

Case report
In this report, a 6 years old girl was presented who was referred to the Pediatric Dep, Shahid Sadoughi Hospital, Yazd, Iran, due to multiple congenital anomalies such as: frontal bossing, horizontal palpebral fissure, small deepest eyes, aplastic nasal bridge, broad philtrum, low set ears, large prominent ears, short neck, microcephaly, pectus excavatum, mental retardation, and dislocation of the hip.

In peripheral blood smear, platelets were decreased but other hematological levels were normal. The karyotype result indicated a mosaic monosomy and partial monosomy of chromosome 21.

Conclusion
According to this and other case reports of monosomy of chromosome 21, this disease had very low prevalence rate among live infants or children. The present case had some congenital anomalies that present with abnormal medical condition. Therefore these patients must be evaluated for chromosomal studies.

Keywords
Congenital anomalies; Chromosome 21; Partial monosomy; Platelets

Corresponding Author:
Sheikhha MH MD PhD, Associate Professor in Genetics, PhD, Genetic Dept. Research & Clinical Centre for Infertility, Yazd, Iran. Email: sheikhha@yahoo.com.

Introduction
Monosomy 21 as a sole cytogenetic abnormality has been reported in a wide variety of hematological disorders, a clear clinical pattern has yet to emerge. Until now, 47 cases of monosomy 21 mosaicism have been described in the literature (1). In this report, a 6 years old girl was presented who was referred to the Pediatric Dep, Shahid Sadoughi Hospital, Yazd, Iran, with partial monosomy of chromosome 21.

Case report
The case is a 6 years old female that was referred to the Pediatric Dept. due to multiple congenital anomalies. She was the first daughter of non-relative parents who was born via normal vaginal delivery. On physical examination, the case had multiple congenital anomalies such as: frontal bossing, horizontal palpebral fissure, small deepest eyes, aplastic nasal bridge, broad philtrum, low set ears, large prominent ears, short neck, microcephaly, pectus excavatum, mental retardation, and dislocation of the hip. In physical examination, there was no lymph adenopathy or thyromegally. The spleen was palpable but there was no hepatomegaly. The lung and heart sounds were normal.

The case had a history of epilepsy at age of 9 months which had been controlled by phenobarbital and nitrazepam tablets. In addition, there was a history of urinary infection with normal findings in sonography. In peripheral blood smear, platlates were decreased but other hematological levels were normal. The cases laboratory data is presented in table 1.

In bone marrow aspiration she had normal cellularity and the megakaryocytic level was increased and myeloid level was seen until neutrophils production.
There was no malignant cell in the blood sample. According to the results of bone marrow aspiration and her clinical condition, 3 times platelets transfusion was done for her. For genetic evolution karyotype was performed. To do this, fifty metaphase spreads were studied on the basis of GTG technique at 450 band resolution. In 11 spread monosomy of chromosome 21 was detected, while in the remaining 39 spreads, 46 chromosomes with marker chromosomes were observed. The marker chromosome is most probably a chromosome 21 with deletion at band distal to q21 (21q21). Therefore the karyotype result indicated a mosaic monosomy and partial monosomy of chromosome 21 (45, XX, - 21 [11] / 46, XX, del (21)(q21) [39]). The cytogenetic test was performed for the parents and it was normal. In view of her parent’s karyotype this chromosomal aberration in the case is of de novo origin, and the mosaic pattern is of post–zygotic origin. It was explained to the parents that the risk of recurrence in future pregnancies is around 1%.

Discussion
In this study, a 6 years old girl with monosomy of chromosome 21 and many congenital anomalies that were presented in her phenotype was reported. By cytogenetic study, she had mosaic monosomy and partial monosomy of chromosome 21. There were some case reports in the literature that have at least some similarities with our case. Chettouh, et al (1995) compared the phenotypes, karyotypes, and molecular data for six cases of partial monosomy 21. In their report 5 regions of chromosome 21 that the deletion of which corresponds to particular features of monosomy 21, were defined.(2) Chang, et al (1995) reported 50 cases of acute nonlymphocytic leukemia (ANLL). Their cytogenetic data showed that 2 patients carry a monosomy 21 abnormality which has been rarely reported in hematologic malignancies. The first case was a 58-year-old male with the diagnosis of AML, FAB M2, who died of refractory leukemia 9 months later. The other case was a 59-year-old female with AML, FAB M2. Complete remission was achieved initially but she died of sepsis 3 months later with no evidence of leukemic relapse (3). Monosomy 21 is not yet recognized as a nonrandom cytogenetic abnormality in ANLL, whereas its unusual predilection in AML, especially the FAB M2 or M4 categories, as noted in the above study, have raised this possibility (3). A patient with full monosomy 21 detected from routine GTG-banded karyotyping was reported by Riegel et al (2005). An unbalanced translocation between the long arms of chromosomes 18 and 21 was found in re-examination of this case with chromosome painting demonstrated (4). Flaherty, et al (1998) presented a case with monosomy 21 that was detected by routine cytogenetics. The fluorescence in situ hybridization (FISH) study demonstrated an unbalanced translocation t(5;21). The patient was partially monosomic for both 5p and 21q (5). Plomp, et al (1998) reported two mentally retarded adults with an unbalanced karyotype resulting from a familial balanced translocation between chromosomes 8 and 21. Both patients had partial trisomy 8p and partial monosomy 21q (6). Orti, et al (1997) reported that deletion of genes from the chromosome 21 region between APP and SOD1 is a potential cause of some of the major phenotypic features of monosomy 21 patients. Furthermore, FISH mapping of two patients with partial monosomy 21 using YAC and cosmid clones defined more accurately the telomeric border of the critical region between markers S226 and S213 (7).

Conclusion
According to other related case reports of monosomy of chromosome 21, this disease had very low prevalence rate among live infants or children. The present case had some congenital anomalies that present with abnormal medical condition. These patients must be evaluated for detecting facial phenotype and other signs that discussed in medical research books.

Conflict of interest
The authors have no conflict of interest.

References
1. Van Dyke DL, Wiktor A. Monosomy 21 in hematologic diseases. Cancer Genet Cytogenet 2003; 142(2):137-141.
2. Chettouh Z, Croquette MF, Delobel B, Gilgenkrants S, Leonard C, Maunoury C et al. Molecular mapping of 21 features associated with partial monosomy 21: involvement of the APP-SOD1 region. Am J Hum Genet 1995; 57(1):62-71.
3. Chang JJ, Liu CJ, Liu JH, Chiou TJ, Tseng CH, Chen PM. Monosomy 21 in two patients with acute nonlymphocytic leukemia. Cancer Genet Cytogenet 1992; 61(2):122-125.
4. Riegel M, Hargreaves P, Baumer A, Gue-Sekic M, Ignjatovic M, Schinzel A. Unbalanced 18q/21q translocation in a patient previously reported as monosomy 21. Eur J Med Genet 2005; 48(2):167-174.
5. Flaherty L, Moloney J, Watson N, Robson L, Bousfield L, Smith A. A case of monosomy 21 found to be an unbalanced de novo t(5p;21q) by fluorescence in situ hybridization. J Intellect Disabil Res 1998; 42 (Pt 3):254-258.
6. Plomp AS, Engelen JJ, Albrechts JC, Die-Smulders CE, Hamers AJ. Two cases of partial trisomy 8p and partial monosomy 21q in a family with a reciprocal translocation (8;21)(p21.1;q22.3). J Med Genet 1998; 35(7):604-608.
7. Orti R, Megarbane A, Maunoury C, Van Broeckhoven C, Sinet PM, Delabar JM. High-resolution physical mapping of a 6.7-Mb YAC contig spanning a region critical for the monosomy 21 phenotype in 21q21.3-q22.1. Genomics 1997; 43(1):25-33.